scholarly journals A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose

2021 ◽  
Vol Volume 14 ◽  
pp. 1215-1222
Author(s):  
Stephan Kress ◽  
Anja Borck ◽  
Ariel Zisman ◽  
Peter Bramlage ◽  
Thorsten Siegmund
Keyword(s):  
Plasma Glucose ◽  
Basal Insulin ◽  
Fasting Glucose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucose Levels ◽  
Prandial Insulin ◽  
Normal Fasting Glucose ◽  
Type 2 Diabetic

scholarly journals Body Mass Index, Fasting Plasma Glucose Levels, and C-peptide Levels as Predictors of the Future Insulin Use in Japanese Type 2 Diabetic Patients

2010 ◽  
Vol 57 (3) ◽  
pp. 237-244 ◽  
Author(s):  
Atsushi GOTO ◽  
Maki TAKAICHI ◽  
Miyako KISHIMOTO ◽  
Yoshihiko TAKAHASHI ◽  
Hiroshi KAJIO ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
C Peptide ◽  
Glucose Levels ◽  
Insulin Use ◽  
Type 2 Diabetic

scholarly journals Changes in β-Cell Function in Offspring of Type-2 Diabetic Patients, as per Fasting and Two-Hour Plasma Glucose Levels

Cureus ◽  
2021 ◽  
Author(s):  
Edavan Pulikkanath Praveen ◽  
Sunil Chouhan ◽  
Jayaprakash Sahoo ◽  
Rajesh Khadgawat ◽  
Madan Lal Khurana ◽  
...  
Keyword(s):  
Plasma Glucose ◽  
Cell Function ◽  
Diabetic Patients ◽  
Β Cell ◽  
Type 2 Diabetic Patients ◽  
Glucose Levels ◽  
Β Cell Function ◽  
Type 2 Diabetic

scholarly journals Impact of Comorbidities, Glycemia at Admission and DPP4 Inhibitors in Type 2 Diabetic Patients with COVID-19: a Case Series from an Academic Hospital in Lombardy, Italy

2020 ◽  
Author(s):  
Marco Mirani ◽  
Giuseppe Favacchio ◽  
Flaminia Carrone ◽  
Nazarena Betella ◽  
Emilia Biamonte ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Case Series ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucose Levels ◽  
Risk Of Mortality ◽  
The Impact ◽  
Type 2 Diabetic

<a>OBJECTIVE</a> <p>Diabetes mellitus may unfavorably influence the outcome of Coronavirus disease-19 (COVID-19), <a>but the determinants of this effect are still poorly understood.</a></p> <p><a>In this monocentric study we aimed at evaluating the impact of type 2 diabetes, comorbidities, plasma glucose levels and </a>antidiabetic medications on the survival of COVID-19 patients.</p> <p>RESEARCH DESIGN AND METHODS</p> <p>This was a case series involving 387 COVID-19 patients admitted to a single center in the region of Lombardy, the epicenter of the <a></a><a>Severe Acute Respiratory Syndrome Coronavirus-2 </a>(SARS-CoV2) pandemic in Italy, between February 20 and April 9, 2020.</p> <p>Medical history, pharmacological treatments, laboratory findings and clinical outcomes of non-diabetic and type 2 diabetic patients were compared. Cox proportional hazards analysis was applied to investigate risk factors associate with mortality.</p> <p>RESULTS</p> <p>Our samples included 90 patients (23.3%) with type 2 diabetes, who displayed double the mortality rate of non-diabetic subjects (42.3% vs 21.7%, <i>P</i> < 0.001). <a>In spite of this, after correction for age and sex, risk of mortality was significantly associated with a history of hypertension [adjusted hazard ratio (aHR) 1.84, 95% confidence interval (C.I.) 1.15-2.95; <i>P </i>= 0.011), coronary artery disease (aHR 1.56, 95% C.I. 1.04-2.35; <i>P </i>= 0.031), chronic kidney disease (aHR 2.07, 95% C.I. 1.27-3.38; <i>P </i>= 0.003), stroke (aHR 2.09, 95% C.I. 1.23-3.55; <i>P</i>=0.006) and cancer (aHR 1.57, 95% C.I. 1.08-2.42; <i>P </i>= 0.04), but not with type 2 diabetes (<i>P </i>= 0.170). </a></p> <p><a>In diabetic patients, elevated plasma glucose </a>(<a>a</a>HR 1.22, 95% C.I. 1.04 – 1.44 per mmol/l; <i>P </i>= 0.015) and IL-6 levels at admission [<a></a><a>aHR 2.47, 95% C.I. 1.28 – 4.78 per 1 standard deviation (SD) increase, <i>P </i>= 0.007</a>] as well as treatments with insulin (aHR 3.05, 95% C.I. 1.57-5.95; <i>P </i>= 0.001) and beta-blockers (aHR 3.20, 95% C.I. 1.50-6.60; <i>P </i>= 0.001) were independently associated with an increased mortality, whereas the use of DPP-4 inhibitors was significantly and independently associated with a lower risk of mortality (aHR 0.13, 95% C.I. 0.02 – 0.92, <i>P </i>= 0.042).</p> <p>CONCLUSIONS</p> <p><a></a><a>Plasma glucose levels at admission and antidiabetic drugs may influence the survival of COVID-19 patients affected by type-2 diabetes</a>.</p> <br>

scholarly journals Impact of Comorbidities, Glycemia at Admission and DPP4 Inhibitors in Type 2 Diabetic Patients with COVID-19: a Case Series from an Academic Hospital in Lombardy, Italy

2020 ◽  
Author(s):  
Marco Mirani ◽  
Giuseppe Favacchio ◽  
Flaminia Carrone ◽  
Nazarena Betella ◽  
Emilia Biamonte ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Case Series ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucose Levels ◽  
Risk Of Mortality ◽  
The Impact ◽  
Type 2 Diabetic

<a>OBJECTIVE</a> <p>Diabetes mellitus may unfavorably influence the outcome of Coronavirus disease-19 (COVID-19), <a>but the determinants of this effect are still poorly understood.</a></p> <p><a>In this monocentric study we aimed at evaluating the impact of type 2 diabetes, comorbidities, plasma glucose levels and </a>antidiabetic medications on the survival of COVID-19 patients.</p> <p>RESEARCH DESIGN AND METHODS</p> <p>This was a case series involving 387 COVID-19 patients admitted to a single center in the region of Lombardy, the epicenter of the <a></a><a>Severe Acute Respiratory Syndrome Coronavirus-2 </a>(SARS-CoV2) pandemic in Italy, between February 20 and April 9, 2020.</p> <p>Medical history, pharmacological treatments, laboratory findings and clinical outcomes of non-diabetic and type 2 diabetic patients were compared. Cox proportional hazards analysis was applied to investigate risk factors associate with mortality.</p> <p>RESULTS</p> <p>Our samples included 90 patients (23.3%) with type 2 diabetes, who displayed double the mortality rate of non-diabetic subjects (42.3% vs 21.7%, <i>P</i> < 0.001). <a>In spite of this, after correction for age and sex, risk of mortality was significantly associated with a history of hypertension [adjusted hazard ratio (aHR) 1.84, 95% confidence interval (C.I.) 1.15-2.95; <i>P </i>= 0.011), coronary artery disease (aHR 1.56, 95% C.I. 1.04-2.35; <i>P </i>= 0.031), chronic kidney disease (aHR 2.07, 95% C.I. 1.27-3.38; <i>P </i>= 0.003), stroke (aHR 2.09, 95% C.I. 1.23-3.55; <i>P</i>=0.006) and cancer (aHR 1.57, 95% C.I. 1.08-2.42; <i>P </i>= 0.04), but not with type 2 diabetes (<i>P </i>= 0.170). </a></p> <p><a>In diabetic patients, elevated plasma glucose </a>(<a>a</a>HR 1.22, 95% C.I. 1.04 – 1.44 per mmol/l; <i>P </i>= 0.015) and IL-6 levels at admission [<a></a><a>aHR 2.47, 95% C.I. 1.28 – 4.78 per 1 standard deviation (SD) increase, <i>P </i>= 0.007</a>] as well as treatments with insulin (aHR 3.05, 95% C.I. 1.57-5.95; <i>P </i>= 0.001) and beta-blockers (aHR 3.20, 95% C.I. 1.50-6.60; <i>P </i>= 0.001) were independently associated with an increased mortality, whereas the use of DPP-4 inhibitors was significantly and independently associated with a lower risk of mortality (aHR 0.13, 95% C.I. 0.02 – 0.92, <i>P </i>= 0.042).</p> <p>CONCLUSIONS</p> <p><a></a><a>Plasma glucose levels at admission and antidiabetic drugs may influence the survival of COVID-19 patients affected by type-2 diabetes</a>.</p> <br>

Sign in / Sign up

Export Citation Format

Share Document